埃替拉韦、考比司他、恩曲他滨和富马酸替诺福韦二吡呋酯单片方案初始治疗资源有限地区2型人类免疫缺陷病毒感染的试验:西非塞内加尔48周结果
该48周开放标签试验在塞内加尔纳入30例未治疗HIV-2成人,评估E/C/F/TDF单片方案。28/30(93.3%;95%CI 77.9%-99.2%)在48周达到病毒抑制,1例失败检出多重耐药。作者认为该方案安全有效且耐受良好,支持使用整合酶抑制剂方案治疗HIV-2。
要点
- E/C/F/TDF单片方案在HIV-2感染者中48周病毒抑制率为93.3%(28/30)。
- 中位CD4计数从基线408 cells/μL升至48周增加161 cells/μL。
- 1例病毒学失败检出K65R、G140S和Q148R耐药突变。
核心结论
- E/C/F/TDF每日一次单片方案在HIV-2感染者中安全、有效且耐受良好,支持使用整合酶抑制剂方案治疗HIV-2。
研究设计与样本
- 48周开放标签试验,纳入未接受抗逆转录病毒治疗、世界卫生组织3-4期疾病或CD4计数<750 cells/μL的HIV-2感染成人。
- 共纳入30例受试者并启动E/C/F/TDF,29例完成48周随访。
主要发现
- 无死亡、无新发艾滋病相关临床事件,1例失访。
- 中位基线CD4计数为408(范围34-747)cells/μL,48周时中位增加161(范围27-547)cells/μL。
- 25例基线HIV-2病毒载量<50 copies/mL血浆;在可检测HIV-2病毒载量者中,中位值为41(范围10-6135)copies/mL。
- 采用改良意向性治疗分析(美国食品药品监督管理局Snapshot法),30例中28例(93.3%;95%置信区间77.9%-99.2%)在48周达到病毒抑制。
- 1例病毒学失败者在48周检出多重耐药HIV-2(逆转录酶突变:K65R;整合酶突变:G140S和Q148R)。
关键数值与推荐
- 病毒抑制率:28/30(93.3%;95%置信区间77.9%-99.2%),采用改良意向性治疗分析(美国食品药品监督管理局Snapshot法)。
- 中位CD4计数变化:基线408(范围34-747)cells/μL,48周增加161(范围27-547)cells/μL。
临床怎么用
- 作者认为E/C/F/TDF每日一次单片方案安全、有效且耐受良好,其发现支持使用整合酶抑制剂方案治疗HIV-2。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an urgent need for safe and effective antiretroviral therapy (ART) for human immunodeficiency virus type 2 (HIV-2) infection. We undertook the first clinical trial of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (E/C/F/TDF) to assess its effectiveness in HIV-2-infected individuals in Senegal, West Africa. METHODS: HIV-2-infected, ART-naive adults with World Health Organization stage 3-4 disease or CD4 count <750 cells/μL were eligible for this 48-week, open-label trial. We analyzed HIV-2 viral loads (VL), CD4 counts, clinical and adverse events, mortality, and loss to follow-up. RESULTS: We enrolled 30 subjects who initiated E/C/F/TDF. Twenty-nine subjects completed 48 weeks of follow-up. The majority were female (80%). There were no deaths, no new AIDS-associated clinical events, and 1 loss to follow-up. The median baseline CD4 count was 408 (range, 34-747) cells/μL, which increased by a median 161 (range, 27-547) cells/μL at week 48. Twenty-five subjects had baseline HIV-2 VL of <50 copies/mL of plasma. In those with detectable HIV-2 VL, the median was 41 (range, 10-6135) copies/mL. Using a modified intent-to-treat analysis (US Food and Drug Administration Snapshot method), 28 of 30 (93.3%; 95% confidence interval, 77.9%-99.2%) had viral suppression at 48 weeks. The 1 subject with virologic failure had multidrug-resistant HIV-2 (reverse transcriptase mutation: K65R; integrase mutations: G140S and Q148R) detected at week 48. There were 8 grade 3-4 adverse events; none were deemed study related. Adherence and acceptability were good. CONCLUSIONS: Our data suggest that E/C/F/TDF, a once-daily, single-tablet-regimen, is safe, effective, and well tolerated. Our findings support the use of integrase inhibitor-based regimens for HIV-2 treatment. CLINICAL TRIALS REGISTRATION: NCT02180438.
引用
- Ba S, Raugi DN, Smith RA, et al. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa. Clin Infect Dis. 2018. PMID: 29672676. doi:10.1093/cid/ciy324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。